Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacokinetic Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

NCT00675350 is registered in ClinicalTrials.gov with ChemGenex Pharmaceuticals as lead sponsor.

NCT NCT00675350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00675350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacokinetic Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
Lead sponsor
ChemGenex Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2008
Completion date
January 31, 2009
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic tumors